There are now multiple phase 3 studies on combination transarterial chemoembolization (TACE) and immunotherapy showing a significant benefit over TACE alone. How do these findings change the hepatocellular carcinoma (HCC) treatment algorithm? In this multidisciplinary episode of the BackTable Podcast, Dr. Richard Finn (Medical Oncologist at UCLA) and Dr. Julius Chapiro (Interventional Radiologist at Yale University) join host Dr. Chris Beck to discuss immunotherapy, TACE, emerging trends in HCC treatment, and the future of the field.
—
This podcast is supported by an educational grant from Guerbet.
—
SYNPOSIS
The doctors highlight the importance of high quality clinical data and the pivotal studies shaping current best practices. They explore the role of the different players on the multidisciplinary team and compare the oncologic and radiologic perspectives. Additionally, they discuss the synergy between TACE and immunotherapy, the criteria for selecting appropriate treatments, and the ongoing need for research and collaboration.
—
TIMESTAMPS
00:00 – Introduction
03:35 – HCC from an Oncologic Perspective
05:33 – Radiological Perspective on Liver Cancer
06:50 – Referral Patterns and Organizing a Multidisciplinary Approach
18:01 – Explaining TACE and Variations in the Procedure
27:27 – Choosing the Right Procedure for HCC
36:13 – Making a Decision on Medical Treatment Candidacy
42:23 – Importance of Data Driven HCC Treatment, Practical Insights, and Studies to Know
55:30 – Planning an Approach for a TACE Procedure
01:02:26 – Final Thoughts and Future Prospects in Liver Cancer Treatment
—
RESOURCES
Barcelona Staging System:
https://www.ncbi.nlm.nih.gov/books/NBK569796/table/Ch3-t0001/
TRACE Trial:
https://pubs.rsna.org/doi/full/10.1148/radiol.211806
PREMIERE Trial:
https://www.gastrojournal.org/article/S0016-5085(16)34971-X/fulltext
EMERALD-1 Trial:
https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.LBA432
LEAP O12 Study:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract